Skip to main content

Table 1 Baseline clinical characteristics of CBF AML patients

From: Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Characteristics

Total (n = 427)

inv (16) (n = 176)

t (8; 21) (n = 251)

P value

Gender, n(%)

   

0.715

 Male

218 (51.1%)

88 (50.0%)

130 (51.8%)

 

 Female

209 (48.9%)

88 (50.0%)

121 (48.2%)

 

Age(y), median(range)

10.9 (0.3–17.9)

10.6 (0.3–17.9)

11.1 (0.6–17.8)

0.059

Race

   

0.002

 White

289 (77.1%)

136 (85.0%)

153 (71.2%)

 

 Nonwhite

86 (22.9%)

24 (15.0%)

62 (28.8%)

 

Ethnicity

   

0.177

 Hispanic or Latino

96 (23.4%)

34 (20.0%)

62 (25.7%)

 

 Not Hispanic or Latino

315 (76.6%)

136 (80.0%)

179 (74.3%)

 

FAB Category

   

 < 0.001

 M1

12 (6.8%)

0 (0.0%)

12 (11.8%)

 

 M2

88 (49.7%)

0 (0.0%)

88 (86.3%)

 

 M4

75 (42.4%)

74 (98.7%)

1 (1.0%)

 

 M5

2 (1.1%)

1 (1.3%)

1 (1.0%)

 

Chemotherapy protocol, n (%)

   

0.387

 AAML1031

229 (53.6%)

90 (51.1%)

139 (55.4%)

 

 AAML0531

198 (46.4%)

86 (48.9%)

112 (44.6%)

 

 Initial WBC (× 109/L), median (range)

30.8 (0.6–478.5)

66.5 (2.2–478.5)

16.5 (0.6–309.3)

 < 0.001

 PB blast(%)

42.0 (0.0–98.0)

43.4 (0.0–94.0)

42.0 (0.0–98.0)

0.730

 BM blast (%)

59.0 (0.0–100.0)

61.5 (6.0–100.0

57.0 (0.0–99.0)

0.166

Risk group, n(%)

   

0.703

 Low risk

419 (98.6%)

172 (98.9%)

247 (98.4%)

 

 High risk

6 (1.4%)

2 (1.1%)

4 (1.6%)

 

CNSL, n(%)

   

0.066

 No

179 (42.4%)

83 (47.7%)

96 (38.7%)

 

 Yes

243 (57.6%)

91 (52.3%)

152 (61.3%)

 

Chloroma

   

0.045

 No

261 (87.0%)

111 (91.7%)

150 (83.8%)

 

 Yes

39 (13.0%)

10 (8.3%)

29 (16.2%)

 

CR status at end of course 1

   

0.062

 CR

353 (84.2%)

149 (86.6%)

204 (82.6%)

 

 Not in CR

59 (14.1%)

18 (10.5%)

41 (16.6%)

 

 Death

7 (1.7%)

5 (2.9%)

2 (0.8%)

 

CR status at end of course 2

   

0.441

 CR

394 (95.2%)

158 (94.0%)

236 (95.9%)

 

 Not in CR

8 (1.9%)

5 (3.0%)

3 (1.2%)

 

 Death

12 (2.9%)

5 (3.0%)

7 (2.8%)

 

GO treatment

   

0.586

 No

56 (50.9%)

21 (47.7%)

35 (53.0%)

 

 Yes

54 (49.1%)

23 (52.3%)

31 (47.0%)

 

Bone Marrow Site of Relapse

   

0.049

 No

341 (73.5%)

137 (68.8%)

204 (77.0%)

 

 Yes

123 (26.5%)

62 (31.2%)

61 (23.0%)

 

CNS Site of Relapse

   

 < 0.001

 No

436 (94.0%)

177 (88.9%

259 (97.7%)

 

 Yes

28 (6.0%)

22 (11.1%)

6 (2.3%)

 

Other Site of Relapse

   

0.704

 No

458 (98.7%)

197 (99.0%)

261 (98.5%)

 

 Yes

6 (1.3%)

2 (1.0%)

4 (1.5%)

 
  1. Abbreviations: WBC white blood cell, PB peripheral blood, BM bone marrow, CNSL central nervous system leukemia, CR complete remission, GO Gemtuzumab ozogamicin